Compass Therapeutics (NASDAQ:CMPX) CAO Neil Lerner Buys 20,000 Shares of Company Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX) CAO Neil Lerner purchased 20,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were acquired at an average price of $0.92 per share, for a total transaction of $18,400.00. Following the completion of the purchase, the chief accounting officer directly owned 420,000 shares of the company’s stock, valued at approximately $386,400. This trade represents a 5.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Neil Lerner also recently made the following trade(s):

• On Thursday, September 24th, Neil Lerner purchased 2,500 shares of Compass Therapeutics stock. The stock was acquired at an average price of $1.14 per share, with a total value of $2,850.00.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $0.90 on Friday. Compass Therapeutics, Inc. has a 1 year low of $0.90 and a 1 year high of $6.88. The stock has a market capitalization of $162.28 million, a PE ratio of -2.25 and a beta of 1.02. The stock has a 50-day simple moving average of $2.00 and a 200-day simple moving average of $2.74.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Analysts predict that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several recent research reports. Wedbush set a $4.00 target price on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Citizens Jmp reduced their price objective on Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 23rd. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They set a “buy” rating and a $5.00 price objective for the company. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.21.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. BVF Inc. IL grew its holdings in shares of Compass Therapeutics by 63.5% during the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after buying an additional 3,014,842 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Compass Therapeutics during the second quarter worth $24,707,000. Sofinnova Investments Inc. increased its stake in Compass Therapeutics by 65.9% in the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock valued at $18,072,000 after purchasing an additional 1,336,560 shares during the last quarter. Palo Alto Investors LP purchased a new position in Compass Therapeutics during the second quarter worth about $12,771,670. Finally, NEXTBio Capital Management LP purchased a new stake in Compass Therapeutics in the 4th quarter valued at about $5,982,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.